AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 281 min read$DBVT

DBV Technologies GAAP EPS of -$0.14 beats by $0.07 (NASDAQ:DBVT)

DBV Technologies reported Q3 GAAP EPS of -$0.14, beating estimates by $0.07. The company posted operating income of $1.6M and had $165.7M in cash as of September 30, 2026, according to a press release.

Original reporting
seekingalpha.com
Published Oct 28, 2026, 9:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DBVT
Bullish
high confidence
Mentioned
$DBVT
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$DBVTBullishMed
01

Why it matters

The earnings beat could generate modest buying pressure, but the company remains unprofitable.

02

Market read

Microcap earnings beat with limited scale; modest trading opportunity.

03

What to watch

Cash balance of $165.7M provides runway, but future funding needs are unclear.

Relevance 6/10Novelty 8/10Timing: after-hours

Background

DBV Technologies reported Q3 results with a GAAP EPS beat.

Company-level read

Ticker impact

$DBVTBullishHigh confidence
Context

Q3 GAAP EPS of -$0.14 beats consensus by $0.07

Expected impact

likely modest upside as market prices in the beat

Evidence & confidence

The beat is a fresh primary disclosure; investors typically reward better-than-expected earnings.

Market effects

Sector

Limited impact; biotech sector may see slight positive sentiment.

Regional

Minor effect on US biotech listings.

Global

Low; microcap earnings have limited global relevance.

Counterpoint

What could challenge this read

The beat is small and the company remains loss-making; price may stay flat.

Key entities

  • company
    DBV Technologies S.A.

    Biotech firm listed on NASDAQ under DBVT.

Read at source← All news

Related articles

OCT 28
$DBVTLow

DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update

DBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update • Submitted the Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in children aged 4-7 Years and requested Prior

SEC EDGAR 8-K2 min
SEP 30
$DBVTMedAI 8/10

DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young Children

DBV Technologies (DBVT) submitted a Biologics License Application to the FDA for its VIASKIN Peanut Patch in children aged 4-7, seeking Priority Review. The patch uses epicutaneous immunotherapy to desensitize children to peanut allergens. The submission follows positive Phase 3 trial results, meeting primary endpoints. DBVT stock closed at $11.55, up to $11.76 in overnight trading.

rttnews.com2 min
SEP 30
$DBVTMedAI 8/10

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

DBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years • The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to

SEC EDGAR 8-K2 min
SEP 29
$DBVTMedAI 8/10

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

DBV Technologies submitted a Biologics License Application to the FDA for its VIASKIN® Peanut Patch for children aged 4-7. The application is supported by positive Phase 3 trial results and seeks Priority Review. The patch uses epicutaneous immunotherapy to treat peanut allergies. DBV's shares trade on Euronext Paris and Nasdaq.

globenewswire.com2 min
JUL 30
$DBVTMedAI 8/10

DBV Technologies S.A.: DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT) (the "Company"), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the...

finanznachrichten.de4 min